Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system

Frontiers in Oncology

Volumn 4 AUG, Issue , 2014, Pages

  Truini, Anna ^a   Alama, Angela ^a   Dal Bello, Maria Giovanna ^a   Coco, Simona ^a   Vanni, Irene ^a   Rijavec, Erika ^a   Genova, Carlo ^a   Barletta, Giulia ^a   Biello, Federica ^a   Grossi, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Biomarker; Circulating tumor cells; CTC; Lung cancer; Predictive marker; Prognostic marker

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CD45 ANTIGEN; CERITINIB; CRIZOTINIB; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; GEFITINIB; GEMCITABINE; PERTUZUMAB; TUMOR MARKER;

BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CELL SEARCH SYSTEM; CIRCULATING TUMOR CELL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INVESTIGATIVE PROCEDURES; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY (TOPIC); NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SHORT SURVEY; SURVIVAL RATE; TREATMENT OUTCOME; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CELL COUNT; FINE NEEDLE ASPIRATION BIOPSY; FLUORESCENCE MICROSCOPY; GENE MUTATION; HEALTH CARE QUALITY; METASTASIS; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; SMALL CELL LUNG CANCER; TREATMENT RESPONSE;

EID: 84906503848     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00242     Document Type: Short Survey

References (31)

1. Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res (2002) 8:2073-84.
2. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res (2004) 10:6897-904.
3. Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol (2011) 178: 989-96. doi:10.1016/j.ajpath.2010.12.003.
4. O'Flaherty JD, Gray S, Richard D, Fennell D, O'Leary JJ, Blackhall FH et al. Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer (2012) 76:19-25. doi: 10.1016/j.lungcan.2011.10.018.
5. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol (2006) 24:4539- 44.
6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin (2013) 63:11-30. doi: 10.3322/caac.21166.
7. Grossi F, Kubota K, Cappuzzo F, de Marinis F, Gridelli C, Aita M et al. Future scenarios for the treatment of advanced non-small cell lung cancer:focus on taxane-containing regimens. Oncologist (2010) 15:1102-12. doi:10.1634/theoncologist.2010-0322.
8. Genova C, Rijavec E, Truini A, Coco S, Sini C, Barletta G et al. Pemetrexed for the treatment of non-small cell lung cancer. Expert Opin Pharmacother (2013) 14:1545- 58.doi: 10.1517/14656566.2013.802774.
9. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 13:239-46. doi: 10.1016/S1470- 2045(11)70393-X.
10. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-anaysis. J Natl Cancer Inst (2013) 105:595-605. doi: 10.1093/jnci/djt072.
11. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 368:2385-94. doi: 10.1056/NEJMoa1214886.
12. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 370:1189-97. doi: 10.1056/NEJMoa1311107.
13. Campos M, Luque R, Jiménez J, Martínez R, Warleta F, Sánchez-Quesada C et al. Simultaneous phenotypic and genetic characterization of single circulating tumor cells from colon cancer patients. Histol Histopathol (2013) 28:1439-50.
14. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 351:781-91.
15. Cohen SJ, Alpaugh RK, Gross S, O'Hara SM, Smirnov DA, Terstappen LW et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer (2006) 6:125-32.
16. Okegawa T, Nutahara K, Higashihara E. Prognostic significance 344 of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol (2009) 181:1091-7. doi: 10.1016/j.juro.2008.11.015.
17. Sawabata N, Okumura M, Utsumi T, Inoue M, Shiono H, Minami M et al. Circulating tumor cells in peripheral blood caused by surgical manipulation of non-small-cell lung cancer: pilot study using an immunocytology method. Gen Thorac Cardiovasc Surg (2007) 55:189-92.
18. Alama A, Truini A, Coco S, Genova C, Grossi F. Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. Drug Discov Today (2014). DOI.10.1016/j.drudis.2014.06.001.
19. Bevilacqua S, Gallo M, Franco R, Rossi A, De Luca A, Rocco G et al. A "live" biopsy in a small-cell lung cancer patient by detection of circulating tumor cells. Lung Cancer (2009) 65:123-5. doi: 10.1016/j.lungcan.2009.01.019.
20. Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, Matsumoto S et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res (2009) 15:6980- 6.
21. Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol (2009) 175:808-16. doi: 10.2353/ajpath.2009.090078.
22. Naito T, Tanaka F, Ono A, Yoneda K, Takahashi T, Murakami H et al. Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol (2012) 7:512-9. doi: 10.1097/JTO.0b013e31823f125d.
23. Hiltermann TJ, Pore MM, van den Berg A, Timens W, Boezen HM, Liesker JJ et al. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol (2012) 23:2937-42. doi:10.1093/annonc/mds138.
24. Normanno N, Rossi A, Morabito A, Signoriello S, Bevilacqua S, Di Maio M et al. Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer. Lung Cancer (2014) May 14. doi: 10.1016/j.lungcan.2014.05.002.
25. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol (2012) 30:525-32. doi: 10.1200/JCO.2010.33.3716.
26. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol (2011) 29:1556-63. doi:10.1200/JCO.2010.28.7045.
27. Hirose T, Murata Y, Oki Y, Sugiyama T, Kusumoto S, Ishida H et al. Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer. Oncol Res (2012) 20:131-7.
28. Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res (2012) 18:2391-401. doi: 10.1158/1078-0432.CCR-11-3148.
29. Muinelo-Romay L, Vieito M, Abalo A, Nocelo MA, Barón F, Anido U et al. Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment. Cancers (Basel) (2014) 6:153-65. doi: 10.3390/cancers6010153.
30. Isobe K, Hata Y, Kobayashi K, Hirota N, Sato K, Sano G et al. Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer. Anticancer Res (2012) 32:3339-44.
31. Swennenhuis JF, Reumers J, Thys K, Aerssens 394 J, Terstappen LW. Efficiency of whole genome amplification of single circulating tumor cells enriched by CellSearch and sorted by FACS. Genome Med (2013) 5:106. doi: 10.1186/gm510.